News >

Frontline Ramucirumab Does Not Improve OS in Gastric Cancer

Jason M. Broderick @jasoncology
Published: Saturday, Dec 09, 2017

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD
Adding ramucirumab (Cyramza) to cisplatin and capecitabine or 5-FU (5-fluorouracil) in the frontline setting did not improve overall survival (OS) in patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to topline results from the phase III RAINFALL trial. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication